patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_968810 | REC_0006601 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.4 | 73 | female | 2 | 17 | 6.5 | 7 | alectinib 600 mg BID | 13.4 | true | MSS | 2026-03-15T05:35:58.473788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991831 | REC_0006602 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 13.2 | 69 | female | 1 | 9 | 6.2 | 5 | entrectinib 600 mg daily | 7.9 | false | MSI-H | 2026-03-15T05:35:58.474019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405444 | REC_0006603 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 13 | 56 | female | 1 | 14 | 7 | 5 | osimertinib 80 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:58.474254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910849 | REC_0006604 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 15.3 | 76 | female | 0 | 17 | 6.6 | 2 | alectinib 600 mg BID | 20.8 | false | MSS | 2026-03-15T05:35:58.474482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809437 | REC_0006605 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.8 | 69 | female | 1 | 22 | 4.3 | 7 | sotorasib 960 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:35:58.474757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984452 | REC_0006606 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 8.6 | 61 | female | 1 | 16 | 7.4 | 6 | alectinib 600 mg BID | 4.7 | false | MSS | 2026-03-15T05:35:58.474991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149738 | REC_0006607 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 23 | 15.2 | 79 | female | 2 | 2 | 5.6 | 0 | pembrolizumab 200 mg q3w | 30.5 | false | MSS | 2026-03-15T05:35:58.475225+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645464 | REC_0006608 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.1 | 64 | female | 1 | 20 | 6.6 | 9 | entrectinib 600 mg daily | 11 | false | MSS | 2026-03-15T05:35:58.475458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131279 | REC_0006609 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 13 | 65 | female | 0 | 11 | 5.5 | 2 | osimertinib 80 mg daily | 19.2 | false | MSS | 2026-03-15T05:35:58.475694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671979 | REC_0006610 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 14.3 | 68 | female | 1 | 12 | 5.7 | 6 | alectinib 600 mg BID | 16.8 | true | MSI-H | 2026-03-15T05:35:58.475924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129727 | REC_0006611 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 5.5 | 76 | female | 2 | 67 | 4.5 | 2 | pembrolizumab 200 mg q3w | 10 | true | MSS | 2026-03-15T05:35:58.476232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400695 | REC_0006612 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 5.4 | 62 | female | 1 | 4 | 4.1 | 2 | pembrolizumab 200 mg q3w | 13.1 | true | MSS | 2026-03-15T05:35:58.476472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904968 | REC_0006613 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 12.9 | 58 | male | 0 | 9 | 5.9 | 7 | osimertinib 80 mg daily | 7.8 | true | MSS | 2026-03-15T05:35:58.476718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417796 | REC_0006614 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 15.2 | 69 | female | 1 | 20 | 6.1 | 2 | entrectinib 600 mg daily | 22.2 | true | MSS | 2026-03-15T05:35:58.476956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503056 | REC_0006615 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 5.3 | 69 | female | 0 | 22 | 5.2 | 7 | pembrolizumab 200 mg q3w | 15.4 | false | MSS | 2026-03-15T05:35:58.477195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369474 | REC_0006616 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 5 | 76 | female | 1 | 8 | 6.2 | 2 | pembrolizumab 200 mg q3w | 24.9 | true | MSS | 2026-03-15T05:35:58.477425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930036 | REC_0006617 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 12.5 | 80 | female | 3 | 20 | 5.3 | 2 | alectinib 600 mg BID | 14.6 | false | MSS | 2026-03-15T05:35:58.477659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829630 | REC_0006618 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 22.8 | 59 | female | 1 | 6 | 7.4 | 5 | alectinib 600 mg BID | 12.8 | true | MSS | 2026-03-15T05:35:58.477954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829926 | REC_0006619 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.2 | 76 | female | 2 | 11 | 5 | 2 | osimertinib 80 mg daily | 25.6 | true | MSS | 2026-03-15T05:35:58.478194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748490 | REC_0006620 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11 | 77 | female | 2 | 10 | 4.6 | 6 | osimertinib 80 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:58.478426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667020 | REC_0006621 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.9 | 72 | female | 2 | 2 | 4.2 | 5 | sotorasib 960 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:58.478660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679028 | REC_0006622 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 12 | 12.3 | 58 | female | 1 | 22 | 6.4 | 3 | alectinib 600 mg BID | 18.1 | true | MSS | 2026-03-15T05:35:58.478896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758198 | REC_0006623 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 5 | 63 | male | 0 | 40 | 5.6 | 6 | pembrolizumab 200 mg q3w | 8.3 | false | MSS | 2026-03-15T05:35:58.479131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146517 | REC_0006624 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 3.8 | 66 | female | 1 | 43 | 2.2 | 5 | pembrolizumab 200 mg q3w | 12.4 | false | MSS | 2026-03-15T05:35:58.479358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374672 | REC_0006625 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 7.6 | 58 | female | 1 | 26 | 3.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.1 | false | MSS | 2026-03-15T05:35:58.479591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234884 | REC_0006626 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 13.7 | 69 | female | 0 | 13 | 5.6 | 3 | sotorasib 960 mg daily | 15.7 | false | MSI-H | 2026-03-15T05:35:58.479823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639858 | REC_0006627 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 10.3 | 75 | male | 2 | 7 | 5 | 2 | entrectinib 600 mg daily | 23.4 | true | MSS | 2026-03-15T05:35:58.480059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287451 | REC_0006628 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 9.6 | 57 | male | 0 | 16 | 3.8 | 1 | sotorasib 960 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:58.480327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451039 | REC_0006629 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.9 | 73 | female | 2 | 21 | 4.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 7.4 | true | MSS | 2026-03-15T05:35:58.480556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437259 | REC_0006630 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.3 | 61 | male | 1 | 7 | 3.3 | 6 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:58.480792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932957 | REC_0006631 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 12.9 | 73 | female | 1 | 3 | 5.9 | 2 | pembrolizumab 200 mg q3w | 20.3 | true | MSS | 2026-03-15T05:35:58.481075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899714 | REC_0006632 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 15.3 | 54 | male | 0 | 11 | 4.7 | 2 | entrectinib 600 mg daily | 20.4 | false | MSI-H | 2026-03-15T05:35:58.481313+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911819 | REC_0006633 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 13.8 | 68 | female | 1 | 21 | 6.5 | 4 | sotorasib 960 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:58.481546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380759 | REC_0006634 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.6 | 65 | female | 1 | 30 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.6 | false | MSS | 2026-03-15T05:35:58.481780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994466 | REC_0006635 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 4.6 | 58 | male | 1 | 18 | 4.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:35:58.482013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959869 | REC_0006636 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 7.8 | 56 | female | 0 | 23 | 5.9 | 0 | pembrolizumab 200 mg q3w | 12.4 | true | MSS | 2026-03-15T05:35:58.482244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716770 | REC_0006637 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12.7 | 64 | male | 0 | 21 | 5.3 | 2 | sotorasib 960 mg daily | 20.8 | false | MSS | 2026-03-15T05:35:58.482480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736385 | REC_0006638 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 8.8 | 69 | female | 1 | 5 | 5.3 | 5 | sotorasib 960 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:58.482708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209027 | REC_0006639 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.8 | 74 | female | 1 | 37 | 2.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.5 | false | MSS | 2026-03-15T05:35:58.482935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709742 | REC_0006640 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 18.6 | 66 | female | 0 | 20 | 4.4 | 6 | sotorasib 960 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:58.483168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121964 | REC_0006641 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.2 | 59 | female | 1 | 19 | 6.5 | 5 | entrectinib 600 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:58.483401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705931 | REC_0006642 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 9.6 | 71 | female | 2 | 14 | 4.5 | 2 | osimertinib 80 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:58.483632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217991 | REC_0006643 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 5.2 | 73 | male | 2 | 6 | 6.4 | 1 | osimertinib 80 mg daily | 24.2 | false | MSS | 2026-03-15T05:35:58.483865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655120 | REC_0006644 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 10.5 | 82 | female | 2 | 21 | 3.8 | 6 | entrectinib 600 mg daily | 16.9 | true | MSI-H | 2026-03-15T05:35:58.484210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109202 | REC_0006645 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10 | 70 | male | 2 | 0 | 7.2 | 8 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:58.484461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459996 | REC_0006646 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 11.9 | 51 | female | 0 | 19 | 5.1 | 1 | alectinib 600 mg BID | 7.3 | false | MSS | 2026-03-15T05:35:58.484698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569916 | REC_0006647 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 7.4 | 55 | female | 1 | 17 | 5 | 7 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:35:58.484934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715650 | REC_0006648 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 10.4 | 64 | female | 1 | 20 | 5 | 2 | osimertinib 80 mg daily | 21.7 | false | MSI-H | 2026-03-15T05:35:58.485184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649984 | REC_0006649 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 3.2 | 63 | female | 1 | 20 | 7.6 | 3 | sotorasib 960 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:58.485418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499163 | REC_0006650 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.4 | 64 | male | 1 | 14 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.7 | true | MSS | 2026-03-15T05:35:58.485652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463971 | REC_0006651 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 16.1 | 68 | female | 1 | 7 | 4.8 | 2 | entrectinib 600 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:35:58.485888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922494 | REC_0006652 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 7.9 | 66 | female | 1 | 15 | 6.6 | 6 | pembrolizumab 200 mg q3w | 17.5 | false | MSS | 2026-03-15T05:35:58.486118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756134 | REC_0006653 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 13 | 5.9 | 62 | male | 0 | 66 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.1 | true | MSS | 2026-03-15T05:35:58.486354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946008 | REC_0006654 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 3.2 | 63 | male | 1 | 64 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.8 | false | MSS | 2026-03-15T05:35:58.486588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899511 | REC_0006655 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 7.6 | 73 | female | 2 | 15 | 7 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:35:58.486815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688098 | REC_0006656 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 15.4 | 63 | female | 0 | 26 | 6.3 | 7 | pembrolizumab 200 mg q3w | 15.6 | false | MSS | 2026-03-15T05:35:58.487050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789287 | REC_0006657 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 8.4 | 62 | male | 0 | 10 | 6.3 | 5 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.487335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660598 | REC_0006658 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15.5 | 56 | male | 1 | 26 | 5.7 | 7 | osimertinib 80 mg daily | 16.7 | true | MSI-H | 2026-03-15T05:35:58.487575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408499 | REC_0006659 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 30 | 10 | 75 | female | 2 | 13 | 4 | 0 | osimertinib 80 mg daily | 28.3 | true | MSS | 2026-03-15T05:35:58.487808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832763 | REC_0006660 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.3 | 63 | female | 1 | 19 | 5.8 | 2 | sotorasib 960 mg daily | 23.1 | false | MSS | 2026-03-15T05:35:58.488043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831963 | REC_0006661 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.7 | 61 | male | 0 | 23 | 6.2 | 5 | alectinib 600 mg BID | 16.9 | true | MSS | 2026-03-15T05:35:58.488417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709240 | REC_0006662 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 9.8 | 76 | female | 2 | 11 | 4.4 | 3 | alectinib 600 mg BID | 12.5 | true | MSS | 2026-03-15T05:35:58.488654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514953 | REC_0006663 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.4 | 58 | male | 1 | 41 | 4.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 4.3 | false | MSS | 2026-03-15T05:35:58.488894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763683 | REC_0006664 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 11.9 | 61 | female | 0 | 20 | 6 | 2 | alectinib 600 mg BID | 20.7 | false | MSI-H | 2026-03-15T05:35:58.489131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322799 | REC_0006665 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 2 | 66 | female | 0 | 20 | 6.8 | 5 | osimertinib 80 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:58.489359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881115 | REC_0006666 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 4.7 | 43 | male | 0 | 12 | 5.1 | 2 | alectinib 600 mg BID | 20.9 | false | MSS | 2026-03-15T05:35:58.489588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529005 | REC_0006667 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 9.3 | 59 | female | 2 | 19 | 4.5 | 5 | pembrolizumab 200 mg q3w | 15.7 | false | MSS | 2026-03-15T05:35:58.489819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396341 | REC_0006668 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 14.8 | 73 | female | 1 | 20 | 8.4 | 2 | alectinib 600 mg BID | 31.6 | true | MSS | 2026-03-15T05:35:58.490058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953278 | REC_0006669 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 9.3 | 58 | female | 0 | 16 | 4.3 | 2 | alectinib 600 mg BID | 9.7 | false | MSS | 2026-03-15T05:35:58.490289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809108 | REC_0006670 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 13.1 | 78 | female | 1 | 19 | 5.1 | 6 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:58.490583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298631 | REC_0006671 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 5.4 | 58 | male | 1 | 61 | 7.4 | 1 | pembrolizumab 200 mg q3w | 21.1 | false | MSS | 2026-03-15T05:35:58.490818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416467 | REC_0006672 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 12.8 | 67 | female | 1 | 11 | 5.4 | 0 | sotorasib 960 mg daily | 36.7 | true | MSS | 2026-03-15T05:35:58.491056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751119 | REC_0006673 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 35 | 7.3 | 70 | female | 2 | 88 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 18 | false | MSS | 2026-03-15T05:35:58.491290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359873 | REC_0006674 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 2.8 | 69 | female | 0 | 14 | 6.2 | 5 | osimertinib 80 mg daily | 4.8 | false | MSS | 2026-03-15T05:35:58.491518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323149 | REC_0006675 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 15.7 | 74 | female | 2 | 12 | 5.5 | 6 | osimertinib 80 mg daily | 16.3 | false | MSI-H | 2026-03-15T05:35:58.491750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747804 | REC_0006676 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.8 | 80 | female | 2 | 19 | 5.8 | 4 | entrectinib 600 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:58.491981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871868 | REC_0006677 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 9.2 | 70 | female | 1 | 17 | 3.1 | 1 | entrectinib 600 mg daily | 21.4 | true | MSS | 2026-03-15T05:35:58.492240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357033 | REC_0006678 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 3.5 | 74 | female | 2 | 11 | 2.6 | 7 | sotorasib 960 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:58.492471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951543 | REC_0006679 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.9 | 61 | female | 1 | 31 | 2.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 11.4 | true | MSS | 2026-03-15T05:35:58.492706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204612 | REC_0006680 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.3 | 68 | male | 0 | 44 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.6 | true | MSS | 2026-03-15T05:35:58.492937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884006 | REC_0006681 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 4.2 | 65 | female | 1 | 20 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.4 | false | MSS | 2026-03-15T05:35:58.493172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907244 | REC_0006682 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.9 | 61 | female | 1 | 21 | 6.3 | 8 | osimertinib 80 mg daily | 7.5 | false | MSS | 2026-03-15T05:35:58.493406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603473 | REC_0006683 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 6.6 | 56 | female | 0 | 18 | 3.7 | 2 | sotorasib 960 mg daily | 20.5 | false | MSS | 2026-03-15T05:35:58.493701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141087 | REC_0006684 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 18.9 | 72 | female | 2 | 9 | 4.6 | 1 | alectinib 600 mg BID | 16.6 | false | MSS | 2026-03-15T05:35:58.493936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531308 | REC_0006685 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 11 | 5 | 68 | female | 0 | 17 | 4.6 | 5 | alectinib 600 mg BID | 14 | false | MSS | 2026-03-15T05:35:58.494169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701746 | REC_0006686 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 5.8 | 63 | male | 1 | 4 | 3.4 | 6 | sotorasib 960 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:58.494400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650248 | REC_0006687 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 7.9 | 72 | male | 3 | 38 | 4.4 | 7 | pembrolizumab 200 mg q3w | 10.2 | true | MSS | 2026-03-15T05:35:58.494636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395916 | REC_0006688 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.6 | 74 | female | 1 | 10 | 6.4 | 1 | osimertinib 80 mg daily | 16.6 | true | MSI-H | 2026-03-15T05:35:58.494868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430103 | REC_0006689 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.3 | 66 | male | 0 | 12 | 4.3 | 6 | sotorasib 960 mg daily | 5.5 | true | MSS | 2026-03-15T05:35:58.495105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840017 | REC_0006690 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 9.1 | 71 | male | 2 | 15 | 4.5 | 8 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:58.495337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688026 | REC_0006691 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.7 | 52 | male | 0 | 9 | 2 | 6 | sotorasib 960 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:58.495569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222560 | REC_0006692 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 17 | 60 | male | 1 | 12 | 4.7 | 5 | pembrolizumab 200 mg q3w | 8.3 | false | MSI-H | 2026-03-15T05:35:58.495802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910393 | REC_0006693 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 15.5 | 67 | female | 0 | 13 | 5.5 | 8 | sotorasib 960 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:58.496030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529443 | REC_0006694 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 8.9 | 60 | male | 0 | 10 | 6.5 | 1 | alectinib 600 mg BID | 26.9 | true | MSS | 2026-03-15T05:35:58.496369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941289 | REC_0006695 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 13 | 10.6 | 76 | female | 2 | 9 | 5.7 | 1 | entrectinib 600 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:58.496607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226934 | REC_0006696 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 18 | 16.1 | 81 | female | 1 | 5 | 6.3 | 2 | pembrolizumab 200 mg q3w | 20.6 | true | MSI-H | 2026-03-15T05:35:58.496904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348378 | REC_0006697 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 13.2 | 68 | female | 1 | 11 | 5.2 | 2 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:58.497155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504693 | REC_0006698 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.9 | 66 | female | 0 | 30 | 3.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 13.5 | false | MSS | 2026-03-15T05:35:58.497386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826045 | REC_0006699 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 9.6 | 56 | male | 0 | 11 | 6.7 | 7 | pembrolizumab 200 mg q3w | 13.4 | false | MSS | 2026-03-15T05:35:58.497623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906600 | REC_0006700 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 5.4 | 68 | female | 1 | 9 | 4.9 | 8 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:35:58.497850+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.